A single-center, single-blind study to investigate skin response to sub-therapeutic doses of taspoglutide in GLP-1 analogue naive healthy volunteers
Completed
- Conditions
- diabetes10018424Diabetes Mellitus type 2
- Registration Number
- NL-OMON34382
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
Inclusion Criteria
Healthy male or female
Age : 18-65 yrs, inclusive
BMI : 20.0-35.0 kg/m2, inclusive
Exclusion Criteria
Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of having participated in more than 3 other drug studies (for men) / more than 2 other drug studies (for women) in the 10 months prior to the start of this study, or when having donated more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior to the start of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method